"Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single-arm, multi-center, real-world study"

作者全名："Cui, Zhaoqiang; Qiu, Zhaohui; Cheng, Wenli; Hu, Wei; Ma, Genshan; Cai, Xiaojun; Jin, Yafei; Zhao, Yi; He, Liqun; Li, Ying; Bu, Peili; Chen, Xiaoping; Wang, Ruxing; Chen, Lin; Dong, Peng; Feng, Liuliu; Han, Xuebin; Hong, Mei; Hou, Yinglong; Liao, Minlei; Wang, Mingliang; Wang, Xiaoyan; Xie, Jianhong; Xu, Yawei; Wang, Zhenxing; Huang, Kai; Li, Yongle; Li, Dongsheng; Ji, Xiaojun; Huang, Jing; Wang, Jun; Fang, Danhong; Wang, Jian'an; Tang, Lijiang; Liu, Yingwu; Fu, Guosheng; Du, Juan; Wang, Ling; Liu, Mengqi; Ge, Junbo"

作者地址："[Cui, Zhaoqiang; Ge, Junbo] Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai, Peoples R China; [Qiu, Zhaohui] Shanghai Tongren Hosp, Dept Cardiol, Shanghai, Peoples R China; [Cheng, Wenli] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China; [Hu, Wei] Cent Hosp Minhang Dist, Dept Cardiol, Shanghai, Peoples R China; [Ma, Genshan] Southeast Univ, Dept Urol, Zhongda Hosp, Nanjing, Peoples R China; [Cai, Xiaojun] Jinan Cent Hosp, Dept Cardiol, Jinan, Peoples R China; [Jin, Yafei] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiol, Guangzhou, Peoples R China; [Zhao, Yi] Dalian Jinzhou First Peoples Hosp, Dept Pathol, Dalian, Peoples R China; [He, Liqun] Wuhan 1 Hosp, Dept Cardiol, Wuhan, Peoples R China; [Li, Ying] Shanghai East Hosp, Dept Cardiol, Shanghai, Peoples R China; [Bu, Peili] Shandong Univ, Dept Cardiol, Qilu Hosp, Jinan, Peoples R China; [Chen, Xiaoping] Sichuan Univ, Dept Cardiol, West China Hosp, Chengdu, Peoples R China; [Wang, Ruxing] Wuxi Peoples Hosp, Dept Cardiol, Wuxi, Peoples R China; [Chen, Lin] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Cardiol, Guangzhou, Peoples R China; [Dong, Peng] Beijing Aviat Gen Hosp, Dept Cardiol, Beijing, Peoples R China; [Feng, Liuliu] Shidong Hosp, Dept Cardiol, Shanghai, Peoples R China; [Han, Xuebin] Shanxi Cardiovasc Hosp, Shanxi Cardiovasc Dis Inst, Dept Cardiol, Taiyuan, Peoples R China; [Hong, Mei] Nanjing Med Univ, Dept Urol, Clin Med Coll 2, Nanjing, Peoples R China; [Hou, Yinglong] Shandong First Med Univ, Affiliated Hosp 1, Dept Cardiol, Jinan, Peoples R China; [Hou, Yinglong] Shandong Prov Qianfoshan Hosp, Jinan, Peoples R China; [Liao, Minlei] Shanghai Gen Hosp, Dept Cardiol, Baoshan Branch, Shanghai, Peoples R China; [Wang, Mingliang] Tongji Univ, Putuo Peoples Hosp, Dept Rheumatol, Shanghai, Peoples R China; [Wang, Xiaoyan] Wuxi Third Peoples Hosp, Dept Cardiol Surg, Wuxi, Peoples R China; [Xie, Jianhong] Zhejiang Prov Peoples Hosp, Dept Cardiol, Hangzhou, Peoples R China; [Xu, Yawei] Shanghai Tenth Peoples Hosp, Dept Cardiol, Shanghai, Peoples R China; [Wang, Zhenxing] Jiangsu Prov Hosp Chinese Med, Dept Cardiol, Nanjing, Peoples R China; [Huang, Kai] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Cardiol, Wuhan, Peoples R China; [Li, Yongle] Tianjin Med Univ, Dept Cardiol, Gen Hosp, Tianjin, Peoples R China; [Li, Dongsheng] Wuhan Third Hosp, Dept Cardiol, Wuhan, Peoples R China; [Ji, Xiaojun] Wenzhou Cent Hosp, Dept Cardiol, Wenzhou, Peoples R China; [Huang, Jing] Chongqing Med Univ, Dept Cardiol, Affiliated Hosp 2, Chongqing, Peoples R China; [Wang, Jun] Jingan Dist Cent Hosp Shanghai, Dept Cardiol, Shanghai, Peoples R China; [Fang, Danhong] Wenzhou Med Univ, Dept Cardiol, Affiliated Hosp 1, Wenzhou, Peoples R China; [Wang, Jian'an] Zhejiang Univ, Affiliated Hosp 2, Dept Cardiol, Sch Med, Hangzhou, Peoples R China; [Tang, Lijiang] Zhejiang Hosp, Dept Cardiol, Hangzhou, Peoples R China; [Liu, Yingwu] Tianjin Third Cent Hosp, Dept Pathol, Tianjin, Peoples R China; [Fu, Guosheng] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Cardiol, Hangzhou, Peoples R China; [Du, Juan; Wang, Ling; Liu, Mengqi] Daiichi Sankyo China Holdings Co Ltd, Med Dept, Shanghai, Peoples R China; [Ge, Junbo] Fudan Univ, Zhongshan Hosp, Dept Cardiol, 180 Fenglin Rd, Shanghai 200032, Peoples R China"

通信作者："Ge, JB (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Cardiol, 180 Fenglin Rd, Shanghai 200032, Peoples R China."

来源：JOURNAL OF CLINICAL HYPERTENSION

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001061417000001

JCR分区：Q2

影响因子：2.8

年份：2024

卷号：26

期号：1

开始页：5

结束页：16

文献类型：Article

关键词：adverse events; blood pressure target; essential hypertension; Olmesartan medoxomil-amlodipine besylate tablet; satisfaction

摘要："There lacks real-world study with a large sample size assessing olmesartan medoxomil-amlodipine besylate (OM-AML) tablet. Therefore, this study aimed to evaluate the efficacy and safety of OM-AML tablet in patients with essential hypertension. Totally, 1341 patients from 36 medical centers with essential hypertension who took OM-AML (20/5 mg) tablet were analyzed in the current prospective, single-arm, multi-center, real-world study (SVK study). Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, week (W)4 and W8 were measured. The mean (& PLUSMN;SE) change of SeSBP/SeDBP was -10.8 & PLUSMN; 0.4/-6.6 & PLUSMN; 0.3 mmHg at W4 and -12.7 & PLUSMN; 0.5/-7.6 & PLUSMN; 0.3 mmHg at W8, respectively. At W4, 78.8% and 29.0% patients achieved BP target by China and American Heart Association (AHA) criteria; at W8, 84.7% and 36.5% patients reached blood pressure (BP) target by China and AHA criteria, accordingly. Meanwhile, 80.2% and 86.4% patients achieved BP response at W4 and W8, respectively. Home-measured SeSBP and SeDBP decreased from W1 to W8 (both p < .001). Besides, patients' and physicians' satisfaction were elevated at W8 compared with W0 (both p < .001). The medication possession rate was 94.8% from baseline to W4 and 91.3% from baseline to W8. The most common drug-related adverse events were nervous system disorders (4.6%), vascular disorders (2.6%), and general disorders and administration site conditions (2.3%) by system organ class, which were generally mild and manageable. In conclusion, OM-AML tablet is one of the best antihypertensive agents in patients with essential hypertension."

基金机构："The authors thank all the investigating groups of the SVK study (Supplementary Table 8) for their contribution and the participants who contributed their information to this study. This study was funded by Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai; Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China"

基金资助正文："The authors thank all the investigating groups of the SVK study (Supplementary Table 8) for their contribution and the participants who contributed their information to this study. This study was funded by Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China."